X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs PROCTER & GAMBLE HEALTH - Comparison Results

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES PROCTER & GAMBLE HEALTH SUVEN LIFESCIENCES/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 19.0 60.8 31.2% View Chart
P/BV x 3.7 10.6 34.9% View Chart
Dividend Yield % 0.6 0.3 192.9%  

Financials

 SUVEN LIFESCIENCES   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-18
PROCTER & GAMBLE HEALTH
Dec-17
SUVEN LIFESCIENCES/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs2511,358 18.5%   
Low Rs155933 16.6%   
Sales per share (Unadj.) Rs49.1665.0 7.4%  
Earnings per share (Unadj.) Rs9.756.6 17.2%  
Cash flow per share (Unadj.) Rs11.472.5 15.7%  
Dividends per share (Unadj.) Rs1.5015.00 10.0%  
Dividend yield (eoy) %0.71.3 56.4%  
Book value per share (Unadj.) Rs60.3441.7 13.6%  
Shares outstanding (eoy) m127.2816.60 766.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.11.7 239.8%   
Avg P/E ratio x20.920.2 103.1%  
P/CF ratio (eoy) x17.815.8 112.7%  
Price / Book Value ratio x3.42.6 129.8%  
Dividend payout %15.426.5 58.2%   
Avg Mkt Cap Rs m25,82519,011 135.8%   
No. of employees `0001.11.5 69.4%   
Total wages/salary Rs m6131,696 36.1%   
Avg. sales/employee Rs Th5,832.67,150.0 81.6%   
Avg. wages/employee Rs Th571.51,098.7 52.0%   
Avg. net profit/employee Rs Th1,153.8608.2 189.7%   
INCOME DATA
Net Sales Rs m6,25311,040 56.6%  
Other income Rs m233240 97.1%   
Total revenues Rs m6,48511,279 57.5%   
Gross profit Rs m1,9821,376 144.0%  
Depreciation Rs m213264 80.7%   
Interest Rs m460-   
Profit before tax Rs m1,9551,352 144.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0170 0.0%   
Tax Rs m718583 123.2%   
Profit after tax Rs m1,237939 131.7%  
Gross profit margin %31.712.5 254.3%  
Effective tax rate %36.743.1 85.2%   
Net profit margin %19.88.5 232.5%  
BALANCE SHEET DATA
Current assets Rs m5,6227,523 74.7%   
Current liabilities Rs m1,1682,253 51.8%   
Net working cap to sales %71.247.7 149.2%  
Current ratio x4.83.3 144.2%  
Inventory Days Days8152 156.1%  
Debtors Days Days3641 88.6%  
Net fixed assets Rs m3,3251,240 268.2%   
Share capital Rs m127166 76.7%   
"Free" reserves Rs m7,5477,167 105.3%   
Net worth Rs m7,6747,333 104.7%   
Long term debt Rs m140-   
Total assets Rs m9,1359,912 92.2%  
Interest coverage x43.2NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.71.1 61.5%   
Return on assets %14.09.5 148.3%  
Return on equity %16.112.8 125.8%  
Return on capital %26.020.8 125.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,0661,015 499.3%   
Fx outflow Rs m2,0013,043 65.8%   
Net fx Rs m3,065-2,028 -151.1%   
CASH FLOW
From Operations Rs m699537 130.3%  
From Investments Rs m-6-476 1.3%  
From Financial Activity Rs m-577-220 262.5%  
Net Cashflow Rs m116-160 -72.9%  

Share Holding

Indian Promoters % 63.4 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 0.0 18.2 -  
FIIs % 0.0 1.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 29.1 125.4%  
Shareholders   37,287 28,591 130.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   PANACEA BIOTECH  DISHMAN PHARMA  TTK HEALTHCARE  NATCO PHARMA  BIOCON   

Compare SUVEN LIFESCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 560 Points Lower; Auto and Banking Stocks Witness Huge Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day deep in the red.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

SUVEN LIFE Announces Quarterly Results (3QFY19); Net Profit Down 27.1% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUVEN LIFE has posted a net profit of Rs 252 m (down 27.1% YoY). Sales on the other hand came in at Rs 1 bn (down 21.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

SUVEN LIFE Announces Quarterly Results (2QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, SUVEN LIFE has posted a net profit of Rs 180 m (down 43.3% YoY). Sales on the other hand came in at Rs 895 m (down 16.2% YoY). Read on for a complete analysis of SUVEN LIFE's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Jul 19, 2019 03:35 PM

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 5-YR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS